Genmab — Oktober 2019

[Solsen]

Jeg er ret sikker på, at de pris
stigninger der er set på revlimid presser daras gennemslagskraft/penetrering i markedet. Måske derfor rabatten øges.

[peter12]

@EL 10:33 I found the origin of July number. Helge wrote August 3,5% higher than July

[peter12]

So 150,2 is correct

[peter12]

I guess

[Bella1]

Intet nyt under kommoden

[Mcjean]

Det er vel ikke urealistisk at 950 nås ultimo 19 samlet, måske endda 1000. Så må vi alt andet lige være nærmere 5bn$ for 2020 end 4bn$. Med en 10% stigning kvartallet næste år endda nærmere 6 end 5. Så analytikerne kan godt finde deres kugleramme frem.

[Mcjean]

Glem de 6, nærmere 4,5-4,8

[E_L]

price went up 5.1% in 2017, 4.9% in 2018 and 4% last januari. I think rebates/discounts probably stable from here into next year. Number of MM patients up 3-4%. So i assume an 8% rise , JUST from this.

[E_L]

2019/2018 growth Y/Y will probably land just above 50%

[E_L]

We will have 1st line in Europe, Japan and US

[E_L]

and SC in H2

[E_L]

you take your guesses, but I agree 4.3-4.5 should be possible

[Plimsoller]

I guess much depends on the schedule for SC. Unfortunately it does not look like it gets PR, or is that too early to say anything about?

[StockBull]

12 Sept var knosensus 4.2 så Genmab guiding for 2020 lander over 4.5 bør det give 10 hurtige % på kursen

[E_L]

i am assuming we don't get PR and get approval somewhere end Q2

[Mcjean]

I dont agree in your 4,3 prediction its too conservative for my taste, are you working in bank?:-) I think they will guide 4.5 and correct it in dec. to 4.8 incl. discounts. Remember chairproblem, more maintenance patient and not 10.000 in clinical trials anymore or?

[StockBull]

JPM har 4.3 for 2020 og 5.1 for 2021.

[Mcjean]

Stockbull hvad er PE ved guiding på 4.5 og kursen ifølge dig? 40 og 2000?

[StockBull]

Kan ikke lige huske pe værdi og har ikke lige mit regneark med på ferie

[E_L]

i did use to work in a bank, yes and yes I do prefer to be a bit conservative and yes, I do remember